Changes in haemostatic parameters during the menstrual cycle and drospirenone-containing oral contraceptive use.

Changes in haemostatic parameters during the menstrual cycle and drospirenone-containing oral contraceptive use. - Yasmin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00005291

Enrollment

Registered

2013-09-20

Start date

2004-04-26

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

procoagulant changes during drospirenone-containing oral contraceptive

Interventions

Group 1: 14 healthy female volunteers without contraindications to combined oral contraceptives were assigned to use drospirenone-containing oral contraceptives containing 3 mg drospirenone and 30 µg

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: No hormonal contraceptives for at least two month prior to start the study.

Exclusion criteria

Exclusion criteria: Pregnancy, lactation, a personal or family history of VT, coagulation disorders or use of medication that might interfere with blood coagulation, contraindications to hormonal contraception.

Design outcomes

Primary

Measure	Time frame
Endogenous thrombin potential, APC resistance, the function of the tissue factor pathway inhibitor-system	—

Secondary

Measure	Time frame
Plasma levels of prothrombin, antithrombin, factor V, factor X, factor VIII, protein C, protein S(total and free) and tissue factor pathway inhibitor (full-length and free).	—

Countries

Sweden

Contacts

Public ContactSvetlana Tchaikovski

Universitätsklinikum Magdeburg Universitätsfrauenklinik

svetlana.tchaikovski@med.ovgu.de0391-67-17310

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026